NDA 204767 · Fresenius Kabi USA
Acetaminophen
Acetaminophen · Intravenous
Last checked: Nov 20, 2026Latest source record: Jul 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Oct 28, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,695
325 Phase 3, 144 recruiting
FAERS reports
260,681
227,384 serious, 51,102 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: Risk of Medication Errors and Hepatotoxicity Take care when prescribing, preparing, and administering Acetaminophen Injection to avoid dosing errors which could result in accidental overdose and death. In particular, be careful to ensure that: the dose in milligrams (mg) and milliliters (mL) is not confused; the dosing is based on weight for patients under 50 kg; infusion pumps are properly programmed; and the total daily dose of acetaminophen from all sources does not exceed maximum daily limits. Acetaminophen Injection contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily limits, and often involve more than one acetaminophen-containing product [see Warnings and Precautions...
What it is approved for
From the label in effect Apr 24, 2024.
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older the reduction of fever in adult and pediatric patients 2 years and older. Acetaminophen Injection is indicated for the Management of mild to moderate pain in adult and pediatric patients 2 years and older ( 1 ) Management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older ( 1 ) Reduction of fever in adult and pediatric patients 2 years and older ( 1 )
Mechanism: The precise mechanism of the analgesic and antipyretic properties of acetaminophen is not established but is thought to primarily involve central actions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ACETAMINOPHEN · ACETAMINOPHEN 1GM/100ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.
OMNI Medical Services, LLCResearch network
NCT03944447 · 200,000 participants (planned) · Start Dec 1, 2018 · Primary completion Dec 31, 2025
Drug: Cannabis, Medical · For: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury and 30 more
Sites: Boca Raton, Florida; Bradenton, Florida; Fort Lauderdale, Florida · 17 sites in all
- A Study of a Candidate COVID-19 Vaccine (COV003)Pivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT04536051 · 10,300 participants (planned) · Start Jun 2, 2020 · Primary completion Sep 2021
Drug: ChAdOx1 nCoV-19 single dose + paracetamol; MenACWY single dose + paracetamol and 2 more · For: Coronavirus
Sites: Salvador, Brazil; Natal, Brazil; Porto Alegre, Brazil · 6 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- To Relieve Pain and Anxiety - an Intervention Study in Ambulance ServicesPivotal-lookingCompleted
Sahlgrenska University HospitalAcademic, hospital or other
NCT00792181 · 2,800 participants (planned) · Start Jun 2008 · Primary completion Nov 2008
Drug: Midazolam · For: Acute Myocardial Infarction; Pain
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- Intravenous Acetaminophen for Postoperative Delirium in Older Patients Recovering From Major Noncardiac SurgeryPivotal-lookingNot yet recruiting
RenJi HospitalAcademic, hospital or other
NCT06653465 · 1,930 participants (planned) · Start Jun 2025 · Primary completion Jun 2027
Drug: Acetaminophen; Saline · For: Delirium in Old Age
- Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02183688 · 1,889 participants · Start Sep 1998 · Primary completion Jan 2003
Drug: Low dose ASA; High dose ASA and 4 more · For: Migraine Disorders
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use23,638
- fatigue21,350
- drug ineffective19,003
- pain18,796
- nausea18,643
- headache17,524
- toxicity to various agents16,809
- dyspnoea15,387
- vomiting14,858
- pyrexia14,826
- arthralgia14,756
- diarrhoea14,066
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,587 |
| 2005 | 2,685 |
| 2006 | 3,149 |
| 2007 | 2,550 |
| 2008 | 3,854 |
| 2009 | 2,962 |
| 2010 | 3,783 |
| 2011 | 8,055 |
| 2012 | 8,038 |
| 2013 | 3,367 |
| 2014 | 4,018 |
| 2015 | 6,103 |
| 2016 | 8,292 |
| 2017 | 7,458 |
| 2018 | 9,197 |
| 2019 | 12,626 |
| 2020 | 19,798 |
| 2021 | 20,049 |
| 2022 | 27,207 |
| 2023 | 27,954 |
| 2024 | 28,656 |
| 2025 | 28,267 |
| 2026 | 20,015 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Acetaminophen (Acetaminophen)
2024 spending
$126K
Beneficiaries
305
734 claims
Per beneficiary
$413
$0.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $35,877 |
| 2022 | $59,928 |
| 2023 | $48,943 |
| 2024 | $125,891 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis.
Tan E, Braithwaite I, McKinlay CJD, et al. · JAMA Netw Open 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Short-term Dual Therapy or Mono Therapy With Acetaminophen and Ibuprofen for Fever: A Network Meta-Analysis.
De la Cruz-Mena JE, Veroniki AA, Acosta-Reyes J, et al. · Pediatrics 2024 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and safety of acetaminophen, topical and oral non-steroidal anti-inflammatory drugs for knee osteoarthritis: evidence from a network meta-analysis of randomized controlled trials and real-world data.
Zeng C, Doherty M, Persson MSM, et al. · Osteoarthritis Cartilage 2021 · Comparative Study, Research Support, Non-U.S. Gov't
- Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies.
Masarwa R, Levine H, Gorelik E, et al. · Am J Epidemiol 2018 · Meta-Analysis, Systematic Review
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Tramadol (with or without acetaminophen) efficacy and harm: Systematic review and meta-analysis.
Otte JA, Chu G, Heran B, et al. · Can Fam Physician 2025 · Systematic Review, Meta-Analysis
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.